Novo Nordisk (NVO) Stock Forecast, Price Target & Predictions
NVO Stock Forecast
Novo Nordisk stock forecast is as follows: an average price target of $158.00 (represents a 52.75% upside from NVO’s last price of $103.44) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
NVO Price Target
The average price target for Novo Nordisk (NVO) is $158.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $160.00 to $156.00. This represents a potential 52.75% upside from NVO's last price of $103.44.
NVO Analyst Ratings
According to 8 Wall Street analysts, Novo Nordisk's rating consensus is 'Buy'. The analyst rating breakdown for NVO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Novo Nordisk Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Evan Seigerman | BMO Capital | $156.00 | $118.58 | 31.56% | 50.81% |
| Sep 11, 2024 | Louise Chen | Cantor Fitzgerald | $160.00 | $135.23 | 18.32% | 54.68% |
| Aug 08, 2024 | Evan David Seigerman | BMO Capital | $160.00 | $126.17 | 26.81% | 54.68% |
| Jun 10, 2024 | Jasper Hellweg | Argus Research | $160.00 | $142.88 | 11.98% | 54.68% |
| May 30, 2024 | James Quigley | Goldman Sachs | $156.00 | $132.68 | 17.58% | 50.81% |
| Apr 12, 2024 | Evan David Seigerman | BMO Capital | $163.00 | $125.40 | 29.98% | 57.58% |
The latest Novo Nordisk stock forecast, released on Oct 17, 2024 by Evan Seigerman from BMO Capital, set a price target of $156.00, which represents a 31.56% increase from the stock price at the time of the forecast ($118.58), and a 50.81% increase from NVO last price ($103.44).
Novo Nordisk Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $156.00 | $159.17 |
| Last Closing Price | $103.44 | $103.44 | $103.44 |
| Upside/Downside | -100.00% | 50.81% | 53.88% |
In the current month, the average price target of Novo Nordisk stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Novo Nordisk's last price of $103.44. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 22, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 17, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 10, 2024 | Cantor Fitzgerald | Outperform | Outperform | Hold |
| Sep 20, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 20, 2024 | BMO Capital | Mixed | Mixed | Hold |
| Sep 11, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 09, 2024 | Cantor Fitzgerald | Outperform | Outperform | Hold |
| Sep 09, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Aug 19, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
| Aug 19, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Aug 19, 2024 | Guggenheim | Buy | Buy | Hold |
| Aug 08, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 02, 2024 | Jefferies | Underperform | Underperform | Hold |
| Jul 02, 2024 | Jefferies | Underperform | Initialise | |
| Jul 01, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Jul 01, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
| Jun 28, 2024 | UBS | Neutral | Neutral | Hold |
| Jun 25, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 10, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Jun 10, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
| May 30, 2024 | Goldman Sachs | Buy | Initialise | |
| Apr 30, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 15, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 12, 2024 | BMO Capital | Outperform | Initialise | |
| Apr 05, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Apr 05, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Mar 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 20, 2024 | Morgan Stanley | Outperform | Outperform | Hold |
| Jan 10, 2024 | William Blair | Market Perform | Market Perform | Hold |
| Apr 25, 2022 | Cowen & Co. | Outperform | Upgrade |
Novo Nordisk's last stock rating was published by BMO Capital on Nov 22, 2024. The company gave NVO a "Outperform" rating, the same as its previous rate.
Novo Nordisk Financial Forecast
Novo Nordisk Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $53.37B | $48.09B | $45.57B | $41.27B | $42.03B | $38.33B | $35.62B | $33.04B | $33.80B | $32.14B | $30.93B | $30.01B | $33.88B | $32.42B | $30.28B | $30.04B | $29.29B | $26.93B | $28.45B |
| Avg Forecast | $90.39B | $83.13B | $78.98B | $77.88B | $78.53B | $70.57B | $69.28B | $63.38B | $62.03B | $57.80B | $56.03B | $52.46B | $47.28B | $44.89B | $40.76B | $38.77B | $37.79B | $34.56B | $32.35B | $32.95B | $31.53B | $30.93B | $31.52B | $31.57B | $31.81B | $30.70B | $29.04B | $28.91B | $153.41B | $178.97B |
| High Forecast | $92.95B | $85.49B | $81.22B | $80.09B | $79.07B | $72.05B | $69.32B | $63.38B | $64.47B | $59.36B | $57.62B | $53.95B | $48.62B | $44.89B | $40.76B | $38.77B | $37.79B | $34.56B | $32.35B | $32.95B | $31.53B | $30.93B | $31.52B | $31.57B | $31.81B | $30.70B | $29.04B | $28.91B | $184.09B | $214.77B |
| Low Forecast | $85.76B | $78.88B | $74.94B | $73.89B | $77.92B | $69.09B | $69.25B | $63.38B | $59.58B | $56.23B | $53.17B | $49.77B | $44.86B | $44.89B | $40.76B | $38.77B | $37.79B | $34.56B | $32.35B | $32.95B | $31.53B | $30.93B | $31.52B | $31.57B | $31.81B | $30.70B | $29.04B | $28.91B | $122.73B | $143.18B |
| # Analysts | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.02% | 1.01% | 1.08% | 1.01% | 1.03% | 1.02% | 1.03% | 1.02% | 1.00% | 0.95% | 1.07% | 1.02% | 0.99% | 1.03% | 1.01% | 0.18% | 0.16% |
Novo Nordisk's average Quarter revenue forecast for Jun 23 based on 1 analysts is $56.03B, with a low forecast of $53.17B, and a high forecast of $57.62B. NVO's average Quarter revenue forecast represents a 5.00% increase compared to the company's last Quarter revenue of $53.37B (Mar 23).
Novo Nordisk EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $27.58B | $10.31B | $23.80B | $21.68B | $21.01B | $13.81B | $17.39B | $16.13B | $18.11B | $11.68B | $15.10B | $15.09B | $17.41B | $9.52B | $15.03B | $14.58B | $15.31B | $14.38B | $14.46B |
| Avg Forecast | $42.70B | $39.27B | $37.31B | $36.79B | $37.10B | $33.34B | $32.73B | $29.94B | $29.30B | $27.30B | $26.47B | $24.78B | $22.33B | $21.34B | $19.38B | $18.43B | $17.97B | $16.43B | $15.38B | $15.67B | $14.99B | $14.71B | $14.99B | $15.01B | $15.13B | $14.60B | $13.81B | $13.75B | $81.91B | $90.93B |
| High Forecast | $43.91B | $40.39B | $38.37B | $37.84B | $37.35B | $34.04B | $32.75B | $29.94B | $30.46B | $28.04B | $27.22B | $25.49B | $22.97B | $21.34B | $19.38B | $18.43B | $17.97B | $16.43B | $15.38B | $15.67B | $14.99B | $14.71B | $14.99B | $15.01B | $15.13B | $14.60B | $13.81B | $13.75B | $98.29B | $109.12B |
| Low Forecast | $40.52B | $37.26B | $35.40B | $34.91B | $36.81B | $32.64B | $32.71B | $29.94B | $28.15B | $26.57B | $25.12B | $23.51B | $21.19B | $21.34B | $19.38B | $18.43B | $17.97B | $16.43B | $15.38B | $15.67B | $14.99B | $14.71B | $14.99B | $15.01B | $15.13B | $14.60B | $13.81B | $13.75B | $65.52B | $72.75B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 0.46% | 1.11% | 1.12% | 1.14% | 0.77% | 1.06% | 1.05% | 1.16% | 0.78% | 1.03% | 1.01% | 1.16% | 0.63% | 1.03% | 1.06% | 1.11% | 0.18% | 0.16% |
1 analysts predict NVO's average Quarter EBITDA for Jun 23 to be $26.47B, with a high of $27.22B and a low of $25.12B. This is -4.01% lower than Novo Nordisk's previous annual EBITDA (Mar 23) of $27.58B.
Novo Nordisk Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $19.81B | $13.59B | $14.40B | $13.32B | $14.21B | $10.89B | $12.12B | $12.12B | $12.62B | $9.32B | $10.30B | $10.63B | $11.90B | $8.72B | $10.19B | $9.60B | $10.45B | $10.75B | $10.16B |
| Avg Forecast | $32.43B | $31.77B | $27.91B | $28.21B | $26.94B | $26.15B | $21.86B | $106.74B | $20.23B | $21.43B | $20.61B | $95.74B | $80.50B | $13.84B | $13.01B | $85.42B | $10.45B | $11.11B | $10.95B | $74.51B | $8.18B | $9.95B | $10.13B | $73.22B | $8.46B | $9.24B | $8.85B | $64.94B | $61.24B | $63.88B |
| High Forecast | $33.62B | $32.94B | $28.94B | $29.25B | $28.47B | $26.41B | $21.87B | $128.08B | $20.84B | $22.63B | $21.37B | $114.89B | $96.60B | $13.84B | $13.01B | $102.50B | $10.45B | $11.11B | $10.95B | $89.41B | $8.18B | $9.95B | $10.13B | $87.87B | $8.46B | $9.24B | $8.85B | $77.93B | $73.49B | $76.66B |
| Low Forecast | $30.27B | $29.65B | $26.05B | $26.33B | $26.33B | $25.90B | $21.85B | $85.39B | $19.61B | $20.22B | $19.24B | $76.59B | $64.40B | $13.84B | $13.01B | $68.33B | $10.45B | $11.11B | $10.95B | $59.61B | $8.18B | $9.95B | $10.13B | $58.58B | $8.46B | $9.24B | $8.85B | $51.95B | $49.00B | $51.11B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.21% | 0.17% | 1.04% | 1.02% | 0.17% | 1.04% | 1.09% | 1.11% | 0.17% | 1.14% | 1.03% | 1.05% | 0.16% | 1.03% | 1.10% | 1.08% | 0.16% | 0.18% | 0.16% |
Novo Nordisk's average Quarter net income forecast for Jun 23 is $20.61B, with a range of $19.24B to $21.37B. NVO's average Quarter net income forecast represents a 4.03% increase compared to the company's last Quarter net income of $19.81B (Mar 23).
Novo Nordisk SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $13.48B | $15.09B | $12.61B | $11.83B | $11.15B | $12.82B | $10.14B | $8.90B | $9.19B | $10.96B | $9.18B | $8.22B | $8.52B | $10.77B | $8.77B | $8.43B | $7.86B | $7.32B | $7.70B |
| Avg Forecast | $25.80B | $23.73B | $22.55B | $22.23B | $22.42B | $20.15B | $19.78B | $18.09B | $17.71B | $16.50B | $16.00B | $14.98B | $13.50B | $12.81B | $11.64B | $11.07B | $10.79B | $9.87B | $9.24B | $9.41B | $9.00B | $8.83B | $9.00B | $9.01B | $9.08B | $8.76B | $8.29B | $8.25B | $41.67B | $48.44B |
| High Forecast | $26.54B | $24.41B | $23.19B | $22.86B | $22.57B | $20.57B | $19.79B | $18.09B | $18.41B | $16.95B | $16.45B | $15.40B | $13.88B | $12.81B | $11.64B | $11.07B | $10.79B | $9.87B | $9.24B | $9.41B | $9.00B | $8.83B | $9.00B | $9.01B | $9.08B | $8.76B | $8.29B | $8.25B | $50.00B | $58.12B |
| Low Forecast | $24.48B | $22.52B | $21.39B | $21.10B | $22.25B | $19.73B | $19.77B | $18.09B | $17.01B | $16.05B | $15.18B | $14.21B | $12.81B | $12.81B | $11.64B | $11.07B | $10.79B | $9.87B | $9.24B | $9.41B | $9.00B | $8.83B | $9.00B | $9.01B | $9.08B | $8.76B | $8.29B | $8.25B | $33.34B | $38.75B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 1.12% | 0.98% | 1.02% | 1.01% | 1.19% | 1.03% | 0.96% | 0.98% | 1.22% | 1.04% | 0.91% | 0.95% | 1.19% | 1.00% | 1.02% | 0.95% | 0.18% | 0.16% |
Novo Nordisk's average Quarter SG&A projection for Jun 23 is $16.00B, based on 1 Wall Street analysts, with a range of $15.18B to $16.45B. The forecast indicates a 18.65% rise compared to NVO last annual SG&A of $13.48B (Mar 23).
Novo Nordisk EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $8.81 | $6.01 | $6.37 | $5.87 | $6.24 | $4.75 | $5.29 | $5.26 | $5.47 | $4.00 | $4.42 | $4.54 | $5.07 | $3.68 | $4.30 | $4.03 | $4.37 | $4.41 | $4.07 |
| Avg Forecast | $7.28 | $7.13 | $6.27 | $6.33 | $6.05 | $5.87 | $4.91 | $5.22 | $4.54 | $4.81 | $4.63 | $4.26 | $2.91 | $3.10 | $2.91 | $2.85 | $2.34 | $2.49 | $2.45 | $2.55 | $1.83 | $2.23 | $2.27 | $2.33 | $1.90 | $2.07 | $1.98 | $2.02 | $3.93 | $3.33 |
| High Forecast | $7.55 | $7.40 | $6.50 | $6.57 | $6.39 | $5.93 | $4.91 | $5.22 | $4.68 | $5.08 | $4.80 | $4.41 | $3.02 | $3.10 | $2.91 | $2.85 | $2.34 | $2.49 | $2.45 | $2.55 | $1.83 | $2.23 | $2.27 | $2.33 | $1.90 | $2.07 | $1.98 | $2.02 | $4.72 | $4.03 |
| Low Forecast | $6.80 | $6.66 | $5.85 | $5.91 | $5.91 | $5.82 | $4.91 | $5.22 | $4.40 | $4.54 | $4.32 | $3.97 | $2.71 | $3.10 | $2.91 | $2.85 | $2.34 | $2.49 | $2.45 | $2.55 | $1.83 | $2.23 | $2.27 | $2.33 | $1.90 | $2.07 | $1.98 | $2.02 | $3.14 | $2.64 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 2.07% | 2.07% | 2.05% | 2.01% | 2.19% | 2.03% | 2.13% | 2.15% | 2.14% | 2.19% | 1.98% | 2.00% | 2.17% | 1.94% | 2.08% | 2.03% | 2.16% | 1.12% | 1.22% |
According to 1 Wall Street analysts, Novo Nordisk's projected average Quarter EPS for Jun 23 is $4.63, with a low estimate of $4.32 and a high estimate of $4.80. This represents a -47.47% decrease compared to NVO previous annual EPS of $8.81 (Mar 23).
Novo Nordisk Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| CVAC | CureVac | $2.95 | $29.00 | 883.05% | Buy |
| NTLA | Intellia Therapeutics | $13.13 | $53.00 | 303.66% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MRNA | Moderna | $40.76 | $104.90 | 157.36% | Hold |
| NVAX | Novavax | $9.00 | $20.33 | 125.89% | Buy |
| CRSP | CRISPR Therapeutics | $44.63 | $77.50 | 73.65% | Buy |
| REGN | Regeneron Pharmaceuticals | $740.01 | $1.14K | 53.40% | Buy |
| SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
| NVO | Novo Nordisk | $108.01 | $158.00 | 46.28% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.58 | $310.60 | 25.96% | Buy |
| VRTX | Vertex Pharmaceuticals | $469.24 | $533.30 | 13.65% | Buy |
| BNTX | BioNTech SE | $117.39 | $126.30 | 7.59% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| DNA | Ginkgo Bioworks | $9.61 | $7.00 | -27.16% | Buy |
| TGTX | TG Therapeutics | $33.57 | $23.75 | -29.25% | Buy |